Osivax ^Partner

Osivax is a clinical-stage biopharmaceutical company based in Lyon, France, with additional locations in Liège, Belgium, and Australia. Founded in 2017 as a spin-off from Imaxio, Osivax specializes in developing universal vaccines aimed at highly mutating respiratory viruses. The company utilizes its proprietary oligoDOM™ self-assembling nanoparticle platform, which effectively targets both T-cell and B-cell immune responses to offer broad-spectrum protection against various viral strains.

The company's lead candidate, OVX836, is a universal influenza vaccine currently in Phase 2 trials, having been tested in over 1,200 subjects. Osivax is also working towards a pan-respiratory vaccine that aims to protect against all influenza strains and COVID-19 variants in a single shot. The company has established strategic partnerships in infectious disease research and has secured funding to support its vaccine development efforts.